Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria Market

Chronic urticaria is a debilitating disease that is characterized by itching and hives with or without angioedema, lasting for more than 6 weeks. Chronic urticaria might be triggered due to stimuli such as stroking or scratching the skin, exercise, emotional upset (cholinergic urticaria), cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Urticaria induced, thus, is known as chronic induced urticaria (CIndU). 

 

However, more commonly chronic urticaria is endogenous and independent of any external causes. This urticaria is known as chronic spontaneous urticaria (CSU).

 

Chronic Spontaneous Urticaria Epidemiological Segmentation

The Epidemiological Segmentation of Chronic Spontaneous Urticaria in 7MM from 2018 to 2030 is segmented as:-

  • Total Prevalent cases of Chronic Spontaneous Urticaria
  • Gender-Specific cases of Chronic Spontaneous Urticaria
  • Chronic Spontaneous Urticaria cases of Age-specific 
  • Total diagnosed and Treatable prevalent cases of Chronic Spontaneous Urticaria


Chronic Spontaneous Urticaria Epidemiology (2020)

  • The total diagnosed prevalent population of Chronic Spontaneous Urticaria in 7MM was 1,182,486.
  • Gender-specific Chronic Spontaneous Urticaria Cases were observed in the United States:-
  • Males- 138,019 cases
  • Females- 373,163 cases
  • The total number of Chronic Spontaneous Urticaria prevalent cases in the United States was found to be 511,182.
  • The total Chronic Spontaneous Urticaria prevalent cases in Germany were 122,708.
  • In Japan, the total number of Chronic Spontaneous Urticaria prevalent cases was observed to be 172,313.
  • The total number of Chronic Spontaneous Urticaria cases in Spain was estimated to be 76,343.


Chronic Spontaneous Urticaria Market

The therapeutic market size of Chronic Spontaneous Urticaria in 7MM in 2020 was USD 1,132.7 million.


Chronic Spontaneous Urticaria Market Drivers

  • Rising prevalent rate
  • New promising drugs in the pipeline
  • Increase in R&D activities 


Chronic Spontaneous Urticaria Market Barriers

  • Lack of understanding of disease pathology
  • Approaching patent cliff
  • The economic burden on patients 


Chronic Spontaneous Urticaria Emerging Drugs

The emerging drugs of the Chronic Spontaneous Urticaria market are:

  • Dupilumab
  • Ligelizumab
  • Benralizumab
  • Fenebrutinib
  • KPL-716
  • LOU064
  • UB-221
  • LY3454738
  • Mepolizumab
  • AK002

And many more


Chronic Spontaneous Urticaria Key Players

The key players in the Chronic Spontaneous Urticaria market are:

  • Sanofi/ Regeneron
  • Novartis Pharmaceuticals
  • AstraZeneca
  • Genentech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Novartis Pharmaceuticals
  • United BioPharma
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Allakos

And many more